Navigation Links
NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011

LAWRENCE, Mass., May 4, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported financial results for the first quarter of 2011 ended March  31, 2011, with total revenue above the top end of its guidance range.


Net revenue for first quarter of 2011 increased 25 percent to a record $50.6 million compared with revenue of $40.4 million for the first quarter of 2010.  The increase was primarily driven by continued strong growth in the Home as a result of increased adoption of home hemodialysis with the NxStage System One™, and solid performance in Critical Care and In-Center.

Home revenue for the first quarter increased 37 percent to a record $26.0 million compared with revenues of $19.0 million for the first quarter of 2010.  

Critical Care revenue increased 23 percent to $7.4 million for the first quarter of 2011 compared with revenues of $6.1 million for the first quarter of 2010.  Revenue in the In-Center market increased to $17.1 million for the first quarter of 2011 compared with revenues of $15.3 million for the first quarter of 2010.  

"In Q1, we continued our trend of delivering solid operating and financial results, and top line revenue ahead of our expectations," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "We continue to be encouraged by evidence that our strategy to increase adoption of home hemodialysis with the System One continues to gain traction. We're focused on maintaining our growth momentum across our business while continuing to execute against our long-term growth strategy, which includes creating appropriate reimbursement for home hemodialysis that is both simple and predictable. We believe we are well positioned to deliver continued improvements and are maintaining our outlook for fiscal 2011."

NxStage reported a net loss of $6.0 million or ($0.11) per share for the first quarter of 2011 compared with a net loss of $9.0 million or ($0.19) per share for the first quarter of 2010.  

For the first quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized and other non-cash expenses, of $1.1 million, compared with an Adjusted EBITDA loss of $1.3 million in the first quarter of 2010.  (See the exhibits for a reconciliation of this non-GAAP measure.)


For the second quarter of 2011, the Company is forecasting revenues to be between $50.0 million and $51.5 million, a net loss in the range of $6.0 to $5.0 million or ($0.11) to ($0.09) per share, and Adjusted EBITDA in the range of $0.5 to $1.5 million.  

This release contains a non-GAAP financial measure.  A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call today, May 4, 2011, at 9:00 a.m. Eastern Time to discuss its first quarter financial results.  To listen to the conference call, please dial 800-510-0178 (domestic) or 617-614-3450 (international).  The passcode is 58429978.  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at

A replay of the conference call will be available 2 hours after the conclusion of the call through May 11, 2011.  To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 63417748.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated growth and opportunities in the Home, Critical Care and In-Center markets, anticipated operating results, including revenue, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our major customers, including DaVita Inc. and Fresenius Medical Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended December 31, 2010.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, and other non-cash expenses) to understand cash generated from or used in operations.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

NxStage Medical, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedMarch 31,20112010Revenues

$50,564$40,408Cost of revenues

32,53128,595Gross profit

18,03311,813Operating expenses:Selling and marketing

9,2108,017Research and development


4,1583,411General and administrative

5,5824,938Total operating expenses

22,66719,401Loss from operations

(4,634)(7,588)Other expense:Interest expense

(1,157)(1,108)Other expense, net

(26)(117)(1,183)(1,225)Net loss before income taxes

(5,817)(8,813)Provision for income taxes

193186Net loss

$ (6,010)$ (8,999)Net loss per share, basic and diluted

$   (0.11)$   (0.19)Weighted-average shares outstanding, basic and diluted

53,42346,971NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)March 31,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$   99,930$
4,339Accounts receivable, net14,79614,107Inventory36,70934,950Prepaid expenses and other current assets2,3552,084Total current assets153,790155,480Property and equipment, net11,3828,290Field equipment, net13,71013,660Deferred cost of revenues40,33940,081Intangible assets, net24,71225,412Goodwill42,69842,698Other assets564473Total assets$ 287,195$
286,094LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$   21,037$
,811Accrued expenses12,90219,537Current portion of long-term debt3143Total current liabilities33,97036,391Deferred revenues55,96755,366Long-term debt41,12740,454Other long-term liabilities4,9851,754Total liabilities136,049133,965Commitments and contingenciesStockholders’ equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of March 31, 2011 and December 31, 2010--Common stock: par value $0.001, 100,000,000 shares authorized; 54,678,198  and 54,043,317 shares issued as of March 31, 2011 and December 31, 2010, respectively5453Additional paid-in capital473,117465,642Accumulated deficit(314,436)(308,426)Accumulated other comprehensive income31485Treasury stock, at cost: 447,929 and 325,104 shares as of March 31, 2011 and December 31, 2010, respectively(7,903)(5,225)Total stockholders’ equity151,146152,129Total liabilities and stockholders’ equity$ 287,195$
286,094NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Three Months EndedMarch 31,20112010Cash flows from operating activities:Net loss

$ (6,010)$ (8,999)Adjustments to reconcile net loss to netcash used in operating activities:Depreciation and amortization

5,6905,464Stock-based compensation


874477Changes in operating assets and liabilities:Accounts receivable


(6,671)(6,654)Prepaid expenses and other assets

(324)(556)Accounts payable

3,985940Accrued expenses and other liabilities

(3,887)2,521Deferred revenues

6023,065Net cash used in operating activities

$ (2,994)$ (1,616)NxStage Medical, Inc.Revenues by Segment(in thousands)Three Months EndedMarch 31,20112010System One segment  Home

9,043  Critical Care

7,4386,059Total System One segment

33,48325,102In-Center segment


40,408NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months EndedMarch 31,20112010Net loss

(9.0)Less: Depreciation, amortization, interest, and taxes

7.16.9Less: Adjusting items*

-0.8Adjusted EBITDA gain (loss)

(1.3)* Adjusting items include stock-based compensation, deferred revenue recognized and other non-cash expensesNxStage Medical, Inc.Non-GAAP Financial Guidance(amounts in millions)Three Months EndedJune 30, 2011High

EstimateNet loss

(6.0)Less: Depreciation, amortization, interest, and taxes

7.07.0Less: Adjusting items*

(0.5)(0.5)Adjusted EBITDA gain

.5* Adjusting items include stock-based compensation, deferred revenue recognized and other non-cash expenses

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):